E
Moderna, Inc.
MRNA
$35.61
$1.313.82%
E
Sell
11/8/2024Downgrade
Moderna, Inc. (MRNA) was downgraded to E+ from D on 11/8/2024 due to a significant decline in the efficiency index, total return index and volatility index.
Moderna, Inc. (MRNA) was downgraded to E+ from D on 11/8/2024 due to a significant decline in the efficiency index, total return index and volatility index.
D
Sell
12/7/2023Downgrade
Moderna, Inc. (MRNA) was downgraded to D from D+ on 12/7/2023 due to a decline in the volatility index and total return index.
Moderna, Inc. (MRNA) was downgraded to D from D+ on 12/7/2023 due to a decline in the volatility index and total return index.
D
Sell
11/6/2023Downgrade
Moderna, Inc. (MRNA) was downgraded to D+ from C- on 11/6/2023 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 163.04% from -$1.38B to -$3.63B, the quick ratio declined from 2.92 to 2.22, and total capital declined 17.7% from $18.12B to $14.91B.
Moderna, Inc. (MRNA) was downgraded to D+ from C- on 11/6/2023 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 163.04% from -$1.38B to -$3.63B, the quick ratio declined from 2.92 to 2.22, and total capital declined 17.7% from $18.12B to $14.91B.
C
Hold
8/1/2023Downgrade
Moderna, Inc. (MRNA) was downgraded to C- from C on 8/1/2023 due to a significant decline in the growth index, valuation index and total return index. Operating cash flow declined 173.71% from $1.66B to -$1.23B, EBIT declined 123.16% from $1.58B to -$366M, and earnings per share declined from $3.6375 to $0.19.
Moderna, Inc. (MRNA) was downgraded to C- from C on 8/1/2023 due to a significant decline in the growth index, valuation index and total return index. Operating cash flow declined 173.71% from $1.66B to -$1.23B, EBIT declined 123.16% from $1.58B to -$366M, and earnings per share declined from $3.6375 to $0.19.
C
Hold
5/4/2023Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 5/4/2023 due to a decline in the total return index and volatility index.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 5/4/2023 due to a decline in the total return index and volatility index.
C
Hold
3/30/2023Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 3/30/2023 due to an increase in the total return index and volatility index.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 3/30/2023 due to an increase in the total return index and volatility index.
C
Hold
3/3/2023Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 3/3/2023 due to a decline in the valuation index and total return index.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 3/3/2023 due to a decline in the valuation index and total return index.
C
Hold
12/30/2022Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 12/30/2022 due to an increase in the efficiency index and volatility index. Total capital increased 2.02% from $18.87B to $19.25B.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 12/30/2022 due to an increase in the efficiency index and volatility index. Total capital increased 2.02% from $18.87B to $19.25B.
C
Hold
8/19/2022Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 8/19/2022 due to a decline in the growth index, total return index and valuation index. Operating cash flow declined 89% from $2.76B to $304M, EBIT declined 42.11% from $4.23B to $2.45B, and earnings per share declined from $8.58 to $5.24.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 8/19/2022 due to a decline in the growth index, total return index and valuation index. Operating cash flow declined 89% from $2.76B to $304M, EBIT declined 42.11% from $4.23B to $2.45B, and earnings per share declined from $8.58 to $5.24.
C
Hold
7/1/2022Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 7/1/2022 due to an increase in the total return index.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 7/1/2022 due to an increase in the total return index.
C
Hold
6/1/2022Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 6/1/2022 due to a decline in the total return index.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 6/1/2022 due to a decline in the total return index.
C
Hold
5/6/2022Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 5/6/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 19.66% from $15.06B to $18.02B.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 5/6/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 19.66% from $15.06B to $18.02B.
C
Hold
12/22/2021Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 12/22/2021 due to a large decline in the total return index and volatility index.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 12/22/2021 due to a large decline in the total return index and volatility index.
C
Hold
12/7/2021Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 12/7/2021 due to a substantial increase in the valuation index and total return index.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 12/7/2021 due to a substantial increase in the valuation index and total return index.
C
Hold
10/15/2021Downgrade
Moderna, Inc. (MRNA) was downgraded to C from C+ on 10/15/2021 due to a significant decline in the total return index and volatility index.
Moderna, Inc. (MRNA) was downgraded to C from C+ on 10/15/2021 due to a significant decline in the total return index and volatility index.
C
Hold
8/6/2021Upgraded
Moderna, Inc. (MRNA) was upgraded to C+ from C on 8/6/2021 due to a major increase in the growth index, total return index and valuation index. EBIT increased 141.86% from $1.27B to $3.06B, earnings per share increased from $2.84 to $6.46, and total revenue increased 124.78% from $1.94B to $4.35B.
Moderna, Inc. (MRNA) was upgraded to C+ from C on 8/6/2021 due to a major increase in the growth index, total return index and valuation index. EBIT increased 141.86% from $1.27B to $3.06B, earnings per share increased from $2.84 to $6.46, and total revenue increased 124.78% from $1.94B to $4.35B.
C
Hold
5/24/2021Upgraded
Moderna, Inc. (MRNA) was upgraded to C from D on 5/24/2021 due to a significant increase in the total return index, growth index and efficiency index. EBIT increased 560.3% from -$275.04M to $1.27B, net income increased 548.1% from -$272.49M to $1.22B, and earnings per share increased from -$0.6869 to $2.84.
Moderna, Inc. (MRNA) was upgraded to C from D on 5/24/2021 due to a significant increase in the total return index, growth index and efficiency index. EBIT increased 560.3% from -$275.04M to $1.27B, net income increased 548.1% from -$272.49M to $1.22B, and earnings per share increased from -$0.6869 to $2.84.
D
Sell
11/12/2019Upgraded
Moderna, Inc. (MRNA) was upgraded to D from D- on 11/12/2019 due to an increase in the growth index, total return index and volatility index. Total revenue increased 30.29% from $13.08M to $17.05M, earnings per share increased from -$0.4103 to -$0.3724, and EBIT increased 9.09% from -$143.94M to -$130.86M.
Moderna, Inc. (MRNA) was upgraded to D from D- on 11/12/2019 due to an increase in the growth index, total return index and volatility index. Total revenue increased 30.29% from $13.08M to $17.05M, earnings per share increased from -$0.4103 to -$0.3724, and EBIT increased 9.09% from -$143.94M to -$130.86M.
D
Sell
10/31/2019Downgrade
Moderna, Inc. (MRNA) was downgraded to D- from D on 10/31/2019 due to a decline in the valuation index.
Moderna, Inc. (MRNA) was downgraded to D- from D on 10/31/2019 due to a decline in the valuation index.
D
Sell
10/15/2019Upgraded
Moderna, Inc. (MRNA) was upgraded to D from D- on 10/15/2019 due to an increase in the total return index.
Moderna, Inc. (MRNA) was upgraded to D from D- on 10/15/2019 due to an increase in the total return index.
D
Sell
8/30/2019Downgrade
Moderna, Inc. (MRNA) was downgraded to D- from D on 8/30/2019 due to a large decline in the volatility index, efficiency index and total return index. Total capital declined 7.25% from $1.48B to $1.37B, and net income declined 1.81% from -$132.66M to -$135.05M.
Moderna, Inc. (MRNA) was downgraded to D- from D on 8/30/2019 due to a large decline in the volatility index, efficiency index and total return index. Total capital declined 7.25% from $1.48B to $1.37B, and net income declined 1.81% from -$132.66M to -$135.05M.
D
Sell
3/12/2019None
Moderna, Inc. (MRNA) was downgraded to D from U on 03/12/2019.
Moderna, Inc. (MRNA) was downgraded to D from U on 03/12/2019.
NASDAQ
03/07/2025 3:00PM Eastern
Quotes delayed
